Summary
For daily laboratory routine work the one-stage clotting assay can be adapted to most indications. For diagnosis of severe hemophilia FVIII levels below 1% can be assessed by a separate calibration. For therapy monitoring and measurement of concentrates ISTH-SCC recommendations should be followed. Measuring »like vs. like« (optimal: assay calibration with concentrate standard the same as the infused concentrate) eliminates the major differences between assay methods. In diagnosis of thrombophilia FVIII levels above and below 150% can be easily differentiated.
Chromogenic assays might be of special use in labeling of B-domain-deleted recombinant concentrates. However, basic causes of the observed assay differences remain (partly) unknown.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 1953; 41: 637–647
Biggs R, Eveling J, Richards G. The assay of antihaemophilic globulin. Br J Haematol 1955; 1: 20–34
Macfarlane RG, Biggs RA.Thrombin Generation Test: The Application in Haemophilia and Thrombocytopenia. J Clin Pathol. 1953; 6:3–8
Mcintosh JH, Owens D, Lee CA, Raut S, Barrowcliffe TW. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost 2003; 1:1005–1011
Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol. 2003; 120: 34–39
White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001; 85:560
Barrowcliffe TW. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost. 1993; 70: 876–877
Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. British Journal of Haematology 2002; 117: 247–248
Barrowcliffe TW, Mertens K, Preston FE, Ingerslev J. Laboratory aspects of haemophilia therapy. Haemophilia. 2002; 8: 244–249
Report of a Joint WHO/WFH/ISTH Meeting: Delivery of Treatment for Hemophilia. London, United Kingdom, 11-13 February 2002. Geneva: WHO, 2002 (http://whqlibdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf)
Lee CA, Owens D, Bray G, Giangrande P, Collins P, Hay C, Gomperts E, Schroth P, Barrowcliffe T. Pharmacokinetics of recombinant factor VIII (recombinate) using onestage clotting and chromogenic factor VIII assay. Thromb Haemost. 1999; 82: 1644–1647
Bertina RM. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb. 2003-2004;33:395–400
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Verlag Berlin Heidelberg
About this paper
Cite this paper
Peetz, D. (2007). Factor VIII Methods: Which Assay Principle for which Indication?. In: Scharrer, I., Schramm, W. (eds) 36th Hemophilia Symposium Hamburg 2005. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-36715-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-540-36715-4_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-36714-7
Online ISBN: 978-3-540-36715-4
eBook Packages: MedicineMedicine (R0)